Corvus Pharmaceuticals, Inc.

David Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026. This transaction marks Moore's first investment in the business.

fool.com - 2026-06-23 15:20:04

SOUTH SAN FRANCISCO, Calif. , June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13. 5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the Company's collaboration partner in China.

globenewswire.com - 2026-06-09 07:30:00

$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States $13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States

globenewswire.com - 2026-06-09 07:30:00

Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-08 13:58:32

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026 Jefferies Global Healthcare Conference, to be held in New York, NY, and the Goldman Sachs 47th Annual Global Healthcare Conference, to be held in Miami, FL. The Jefferies presentation is scheduled for Wednesday, June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is scheduled for Monday, June 8, 2026 at 11:20 AM ET.

globenewswire.com - 2026-05-20 16:01:00

Corvus Pharmaceuticals, Inc. remains a Sell as its valuation has run ahead of fundamentals following encouraging but limited Phase 1 AD data. Soquelitinib shows activity in atopic dermatitis, but questions remain on safety, durability, and efficacy in broader populations versus established treatments. My DCF analysis yields a fair value of $10.07/share, implying 16% downside from current levels, with significant future cash needs likely requiring dilution.

seekingalpha.com - 2026-05-19 13:34:11

Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.

fool.com - 2026-05-17 16:26:06

Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript

seekingalpha.com - 2026-05-14 18:50:45

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy Immunologic markers consistent with soquelitinib's novel mechanism of action and clinical results SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif.

globenewswire.com - 2026-05-14 07:00:00

Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting the potential for drug-free remissions with soquelitinib to be presented at Society for Investigative Dermatology (SID) annual meeting Company hosting investor and analyst meeting to review SID data on May 14, 2026 at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2026.

globenewswire.com - 2026-05-07 16:01:00

SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company's Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology.

globenewswire.com - 2026-04-23 07:30:00

Two oral presentations including late-breaker at SID  Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free remissions Investor and analyst meeting scheduled for 1:30 pm ET (12:30 pm CT) on May 14, 2026 Company to report first quarter 2026 financial results on May 7, 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that it will host an in-person and virtual investor and analyst meeting on May 14, 2026 to highlight soquelitinib data being presented at the Society for Investigative Dermatology (SID) Annual Meeting, which is taking place May 13-16, 2026 in Chicago.

globenewswire.com - 2026-04-21 07:30:00